Akebia Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$340.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Akebia Therapeutics's estimated annual revenue is currently $235M per year.(i)
  • Akebia Therapeutics received $85.0M in venture funding in March 2018.
  • Akebia Therapeutics's estimated revenue per employee is $436,803
  • Akebia Therapeutics's total funding is $340.9M.

Employee Data

  • Akebia Therapeutics has 538 Employees.(i)
  • Akebia Therapeutics grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease. For more information, please visit our website at www.akebia.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$340.9M

Total Funding

538

Number of Employees

$235M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Akebia Therapeutics News

2021-10-29 - Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmace ...

2021-11-15 - Akebia Therapeutics to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present at the Jefferies London Heal ...

2021-11-24 - Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Of ...

09/03/2019 - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and ...

09/08/2019 - Is Akebia Therapeutics, Inc. (AKBA) a great play right now?

On Tuesday, shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) marked $4.11 per share versus a previous $4.13 closing price. With having ...

09/03/2019 - Akebia Therapeutics, Inc. (AKBA) Down -3.89%: Why This Stock Is Killing Today

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is among the top losers of the stock market today, sinking -3.89% or (-0.16 points) to $3.95 from its ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$101.3M5404%N/A
#2
$84.5M54558%N/A
#3
$86.8M56047%$775M
#4
$74.2M5826%N/A
#5
$131M582N/AN/A

Akebia Therapeutics Funding

DateAmountRoundLead InvestorsReference
2008-12-22$15.1MAArticle
2009-07-29$16.0MUndisclosedNovartis Bioventures Ltd, Venture Investors LLCArticle
2011-04-27$22.0MUndisclosedNovartis Venture Fund, Venture Investors LLCArticle
2012-01-10$4.1MSeries BNovartis Bioventures, Venture InvestorsArticle
2013-06-05$41.0MCSatter Investment Management LArticle
2015-04-24$64.6MUndisclosedUBS Investment BankArticle
2017-07-07$67.0MUndisclosedMorgan StanleyArticle
2018-03-26$85.0MUndisclosedMorgan StanleyArticle